The Food and Drug Administration proposed on Thursday to streamline its regulation of health software tools, but remained largely silent on the crucial question of how it will treat products that rely on artificial intelligence, experts said.

The agency’s draft guidance on so-called clinical decision support tools is a long-awaited attempt to define the rules in a regulatory gray area where many new products are promising to change the delivery of medicine. The experts said the document appears to broadly grant latitude to developers of software that helps doctors diagnose and treat a range of conditions, including cancer, diabetes, and heart disease.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy